Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.34 |
| ▸ | TOP1 | P11387 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5517717 | 1.00 | LMNA (0.50) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL5520896 | 1.00 | LMNA (0.50) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL9355138 | 0.79 | LMNA (0.52) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL92729 | 0.73 | LMNA (0.58) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL2297555 | 0.73 | LMNA (0.58) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL1668363 | 0.73 | LMNA (0.58) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL19741239 | 0.73 | LMNA (0.58) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL1964137 | 0.73 | LMNA (0.58) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL6700235 | 0.73 | LMNA (0.58) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL4996629 | 0.73 | LMNA (0.58) | LMNAL3MBTL1TDP1KDM4EPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070042030-A1 | Preparation for the application of agents in mini-droplets | IDEA AG (DE) | 2007-02-22 | — | — | US | disclosed |
| EP-0475160-B2 | Preparation for drug application in minute droplet form | IDEA AG (DE) | 2004-07-14 | — | — | EP | disclosed |
| US-6165500-A | Preparation for the application of agents in mini-droplets | IDEA AG (DE) | 2000-12-26 | — | — | US | disclosed |
| EP-0475160-B1 | Preparation for drug application in minute droplet form | IDEA AG (DE) | 1996-02-14 | — | — | EP | disclosed |
| EP-0475160-A1 | Preparation for drug application in minute droplet form | Cevc, Gregor, Prof. Dr. (DE) | 1992-03-18 | — | — | EP | disclosed |
| WO-1992003122-A1 | PREPARATION FOR APPLICATION OF ACTIVE SUBSTANCES IN THE FORM OF MINIMUM-SIZED DROPLETS | CEVC GREGOR (DE) | 1992-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042030-A1 | Preparation for the application of agents in mini-droplets | FABP4, NPC1L1, LIPA | LMNA 327/4885L3MBTL1 3706/4885TDP1 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.